Alternative names:
SARS-CoV-2 Delta variant

Data and images for Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)

Figures

Figure 1

View details
Cell-based RBD binding assay
. Schematic overview illustrating how our biotinylated RBD can be applied to analyze binding to ACE2-expressing cells.
Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant spike monomer is biologically functional and shows a titratable, high-affinity binding to cell surface ACE2.

Figure 1

Cell-based RBD binding assay
. Schematic overview illustrating how our biotinylated RBD can be applied to analyze binding to ACE2-expressing cells.
Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant spike monomer is biologically functional and shows a titratable, high-affinity binding to cell surface ACE2.

Figure 2

View details
Results of the cell-based binding assay using biotinylated Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK).
ACE2-expressing cells (Vero E6 cells) were incubated with biotinylated recombinant SARS-CoV-2 RBD of the wild-type, Wuhan variant (Recombinant SARS-CoV-2 RBD (HEK)-Biotin) and the SARS-CoV-2 variant B.1.617.2, Delta (Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)-Biotin).
Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant RBD is biologically functional and shows a titratable, high-affinity binding to cell surface ACE2.

Figure 2

Results of the cell-based binding assay using biotinylated Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK).
ACE2-expressing cells (Vero E6 cells) were incubated with biotinylated recombinant SARS-CoV-2 RBD of the wild-type, Wuhan variant (Recombinant SARS-CoV-2 RBD (HEK)-Biotin) and the SARS-CoV-2 variant B.1.617.2, Delta (Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)-Biotin).
Different protein concentrations were used, and ACE2-bound spike protein was subsequently detected by fluorescent staining with streptavidin-PE. Quantification of stained cells at different protein concentrations illustrates that Miltenyi Biotec's recombinant RBD is biologically functional and shows a titratable, high-affinity binding to cell surface ACE2.

Figure 3

View details
SDS-PAGE of biotinylated Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)
under reduced (R) and non-reduced (NR) conditions.

Figure 3

SDS-PAGE of biotinylated Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)
under reduced (R) and non-reduced (NR) conditions.

Figure 4

View details
Size-exclusion chromatography (SEC) Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK).
The non-biotinylated protein was analyzed and the peak corresponds to the monomeric protein.

Figure 4

Size-exclusion chromatography (SEC) Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK).
The non-biotinylated protein was analyzed and the peak corresponds to the monomeric protein.

Specifications for Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)

Overview

The receptor binding domain (RBD) locates C-terminally within the S1 subunits of the spike (S) protein. The S protein forms a homotrimeric structure on the surface of the SARS-CoV-2 virus and binds to the angiotensin-converting enzyme 2 (ACE2) receptor of target cells. Recent studies have shown that the predominant activated form displays one RBD rotated upwards into an ACE2-accessible state and it is known that binding of RBD to ACE2 is a major contributor for interaction of the S protein with its target receptor.
The SARS-CoV-2 mutant strain B.1.617.2, also known as Delta variant, was first identified during the Covid-19 pandemic in India in late 2020. Due to increased transmissibility it spread rapidly around the globe. The B.1.617.2 lineage differs from the wild-type sequence by multiple amino acid mutations of which two key amino acid substitutions L452R and T478K occur in the RBD. The L452R mutation is suspected to confer increased affinity of the RBD to the ACE2 receptor and may decrease recognition of the B.1.617.2 lineage by the immune system.
The SARS-CoV-2 RBD B.1.617.2 (HEK) protein covers amino acids R319 to S591 of the spike protein and contains the L452R and T478K mutations, as well as a C-terminal His-tag and a N-terminal AviTag. Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)-Biotin is specifically biotinylated at a single site, preserving full functionality of the RBD.

Alternative names

SARS-CoV-2 Delta variant

Related products for
Recombinant SARS-CoV-2 RBD B.1.617.2 (HEK)

9 products available | view all